ArticleHeliyon2022

Corrigendum to "Lenvatinib plus sintilimab versus lenvatinib monotherapy as first-line treatment for advanced HBV-related hepatocellular carcinoma: A retrospective, real-world study" [Heliyon 8 (6) (2022) e09538].

Lei Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.